Bristol Myers nabs approval for Opdivo combo as first-line bladder cancer treatment

Bris­tol My­ers Squibb won an­oth­er ap­proval for its block­buster can­cer drug Op­di­vo, this time to treat a type of blad­der can­cer in com­bi­na­tion with chemother­a­pies, the FDA an­nounced Wednes­day.

The FDA ap­proved nivolum­ab, mar­ket­ed as Op­di­vo, to be ad­min­is­tered in com­bi­na­tion with the chemother­a­pies cis­platin and gem­c­itabine to treat adults with un­re­sectable or metasta­t­ic urothe­lial car­ci­no­ma. The ap­proval was based on pos­i­tive re­sults from BMS’ Check­Mate-901 tri­al, which eval­u­at­ed over­all sur­vival and pro­gres­sion-free sur­vival in about 600 pa­tients who had not pre­vi­ous­ly re­ceived treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.